Efficacy of low molecular weight heparin for chronic obstructive pulmonary disease and respiratory failure
A protocol of systematic review of randomized controlled trials
Dejun Zhao, MMa, Jun-Fei Feng, MMb

Abstract
Background: Evaluating the efficacy and safety of low molecular weight heparin (LMWH) for patients with chronic obstructive pulmonary disease (COPD) and respiratory failure (RF) is a major purpose of this study.
Methods: The following electronic databases will be comprehensively retrieved from the inception to July 1, 2019: Cochrane Library, PUBMED, EMBASE, Google Scholar, Web of Science, Allied and Complementary Medicine Database, WANGFANG, and China National Knowledge Infrastructure without language restrictions. All randomized controlled trials related to LMWH for COPD and RF will be included. Two authors will carry out study selection, data collection, and risk of bias assessment independently.
Results: This study will systematically explore the efficacy and safety of LMWH for COPD and RF. The primary outcome is lung function. The secondary outcomes are severity of dyspnea on exertion, quality of life, body mass index, airflow obstruction; and any expected and unexpected adverse events.
Conclusion: The findings of this study will provide evidence to judge whether LMWH is an effective treatment for patients with COPD and RF.
PROSPERO registration number: PROSPERO CRD42019 139631.
Abbreviations: COPD = chronic obstructive pulmonary disease, LMWH = low molecular weight heparin, RCTs = randomized controlled trials, RF = respiratory failure.
Keywords: low molecular weight heparin, chronic obstructive pulmonary disease, respiratory failure, randomized controlled trial, efficacy, safety

1. Introduction
Chronic obstructive pulmonary disease (COPD) is one of the most common lung diseases in the clinical practice.[1,2] It also has been estimated as the third leading cause of death.[3,4] It is characterized by airflow limitation and chronic airway inflammation.[5–8] Patients with such condition often experience increase in cough, sputum production, and dyspnea.[9,10] If COPD is not managed effectively and timely, it can cause respiratory failure (RF) in patients with such disorder.[11–15]

Previous studies have reported that low molecular weight heparin (LMWH) can be used to treat patients with COPD and RF.[16–21] However, no systematic study has been conducted to investigate the efficacy and safety of patients with COPD and RF. Thus, this study will explore the efficacy and safety of LMWH for the treatment of patients with COPD and RF.

2. Methods and analysis
2.1. Ethics and dissemination
This study does not need ethical approval because no individual data will be used. We expect to publish the results of this study at a peer-reviewed journal.

2.2. Study inclusion and exclusion criteria
2.2.1. Types of studies. All randomized controlled trials (RCTs) of using LMWH for patients with COPD and RF will be included with no language limitation.

2.2.2. Types of interventions. Experimental intervention must include LMWH in any forms.
Comparison intervention can be any treatments except any forms of LMWH.

2.2.3. Types of participants. Patients with COPD and RF will be considered for inclusion in spite of race, sex, age, education background, and economic status.

2.2.4. Types of outcome measurements. Primary outcome includes lung function, which can be measured by forced expiratory volume in 1 second or any other related tools.

Secondary outcomes consist of severity of dyspnea on exertion, as measured by any relevant scales, such as the 6-minute walk test scale; quality of life, as assessed by St. George’s Respiratory Questionnaire or other tools; body mass index; airflow obstruction; and any expected and unexpected adverse events.

2.3. Search methods for the identification of studies

2.3.1. Electronic database searches. The following electronic databases will be searched comprehensively from inception to July 1, 2019: Cochrane Library, PUBMED, EMBASE, Google Scholar, Web of Science, Allied and Complementary Medicine Database, WANGFANG, and China National Knowledge Infrastructure without language restrictions. All RCTs related to the LMWH for COPD and RF will be considered with no language limitation. The detailed search strategy for Cochrane Library is presented in Table 1. We will also adapt similar retrieval strategy to the other electronic databases.

2.3.2. Other literature sources search. The reference lists of included RCTs and conference proceedings will be searched to avoid missing any eligible studies.

2.4. Data collection and analysis

2.4.1. Selection of studies. Titles and abstracts of all searched records will be screened by 2 independent authors, focusing on identifying eligible studies and excluding duplicated or irrelevant studies according to the eligibility criteria. Full texts of possible trials will be further obtained if necessary. Any disagreements between 2 authors will be solved by a third author via discussion. The study selection is showed in the flowchart.

2.4.2. Data extraction and management. Before data extraction, we will create a standard data extraction sheet including the following information: title, first author, year of publication, location, participant characteristics, eligibility criteria, sample size, study setting, study methods, randomization, blinding, treatment details, controls, outcomes, safety, conflicts of interest, and other information. All data collection will be extracted by 2 independent authors. A third author will be involved to solve any disagreements between 2 authors by discussion. Any insufficient or missing information will be inquired by contacting primary authors.

2.5. Study quality assessment

Two authors will independently assess the risk of bias for all included studies using Cochrane risk of bias tool. Seven domains of this tool will be evaluated, and each one will be further divided into 3 levels: low, unclear and high risk of bias. A third author will be set to solve all disagreements between 2 authors.

2.6. Treatment effect measurements

Continuous variables will be presented as mean difference or standard mean difference and 95% confidence intervals, while dichotomous values will be exerted as risk ratio and 95% confidence intervals.

2.7. Statistical analysis

We will utilize RevMan 5.3 software to carry out statistical analysis. $I^2$ test is used to investigate heterogeneity among included studies. $I^2 \leq 50\%$ indicates having acceptable heterogeneity, and we will use a fixed-effects model. We will also conduct meta-analysis if it is possible. On the other hand, $I^2 > 50\%$ means having significant heterogeneity, and we will use a random-effects model. In addition, subgroup analysis will be carried out to investigate the possible causes. If there is still substantial heterogeneity after subgroup analysis, descriptive summary will be reported.

2.8. Additional analysis

2.8.1. Subgroup analysis. Subgroup analysis will be performed if the data are sufficient based on the different treatments, controls and outcomes.

2.8.2. Sensitivity analysis. Sensitivity analysis will be carried out to assess the impact of study design, and methodological quality.

2.8.3. Reporting bias. We will identify any reporting bias among eligible studies using funnel plot and Egger regression test if included studies are sufficient.$^{[22,23]}$

| Table 1 | Search strategy for Cochrane Library. |
|---------|--------------------------------------|
| Number  | Search terms                          |
| 1       | Mesh descriptor: (pulmonary disease, chronic obstructive) explode all trees |
| 2       | Mesh descriptor: (respiratory insufficiency) explode all trees |
| 3       | (pulmonary’) or (lung’) or (chronic’) or (obstructive’) or (respiratory’) or (failure’) or (cough’) or (respiratory failure’):ti, ab, kw |
| 4       | Or 1-3 |
| 5       | Mesh descriptor: (heparin, low-molecular-weight) explode all trees |
| 6       | (heparin’) or (low-molecular-weight’) or (anticoagulant’) or (unfractionated heparin’) or (LMWH’):ti, ab, kw |
| 7       | Or 5-6 |
| 8       | MeSH descriptor: (randomized controlled trials) explode all trees |
| 9       | (random’) or (blind’) or (control’) or (allocation’) or (placebo’) or (or clinical trials’) or (controlled trial’):ti, ab, kw |
| 10      | Or 8-9 |
| 11      | 4 and 7 and 10 |
3. Discussion

Although a variety of studies have shown that LMWH is effective in treating patients with COPD and RF, the evidence of LMWH in relieving COPD and RF is still insufficient. In order to systematically investigate the efficacy and safety of LMWH on all aspects of COPD and RF treatment, the goal of this study is to include adequate researches to ensure sufficient evidence. We expect LMWH to have a more positive impact on patients with COPD and RF. This result of this study may help provide more reliable evidence for the enhancement of LMWH management and application in the treatment of COPD and RF.

Author contributions

Conceptualization: De-jun Zhao, Jun-fei Feng.
Data curation: De-jun Zhao, Jun-fei Feng.
Funding acquisition: De-jun Zhao.
Investigation: De-jun Zhao.
Methodology: De-jun Zhao, Jun-fei Feng.
Project administration: De-jun Zhao.
Resources: Jun-fei Feng.
Software: De-jun Zhao, Jun-fei Feng.
Supervision: De-jun Zhao.
Validation: De-jun Zhao, Jun-fei Feng.
Visualization: De-jun Zhao, Jun-fei Feng.
Writing – original draft: De-jun Zhao, Jun-fei Feng.
Writing – review & editing: De-jun Zhao, Jun-fei Feng.

References

[1] Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med 2019;381:1237–66.
[2] Yin HL, Yin SQ, Lin QY, et al. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: a meta-analysis. Medicine (Baltimore) 2017;96:e836.
[3] Chung VC, Wu X, Ma PH, et al. Chinese herbal medicine and salmeterol and fluticasone propionate for chronic obstructive pulmonary disease: systematic review and network meta-analysis. Medicine (Baltimore) 2016;95:e3702.
[4] Rothnie KJ, Yan R, Smeeth L, et al. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015;5:e007824.
[5] Young RP, Hopkins RJ. Chronic obstructive pulmonary disease (COPD) and lung cancer screening. Trans Lung Cancer Res 2018;7:347–60.
[6] Cao YQ, Dong LX, Cao J. Pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Chin Med J (Engl) 2018;131:1732–7.
[7] Pavord ID. Biologics and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018;141:1983–91.
[8] Allison JP, Wedzicha JA. Update in chronic obstructive pulmonary disease 2016. Am J Respir Crit Care Med 2017;196:414–24.
[9] Yoon HK, Park YB, Ree CK, et al. Summary of the chronic obstructive pulmonary disease clinical practice guideline revised in 2014 by the Korean academy of tuberculosis and respiratory disease. Tuberc Respir Dis (Seoul) 2017;80:230–40.
[10] Singh D. Pharmacological treatment for COPD; GOLD 2017 changes direction. Br J Clin Pharmacol 2017;83:933–7.
[11] O’Donnell DE, Parker CM. COPD exacerbations: pathophysiology. Thorax 2006;61:354–61.
[12] Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001;134:600–20.
[13] Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108:435–52S.
[14] Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224–38.
[15] Esquinas AM, Matsuoaka Y, Stiegler S. Predicting survival after acute exacerbation chronic obstructive pulmonary disease (ACOPD): is long-term application of noninvasive ventilation the last life guard? Int J Chron Obstruct Pulmon Dis 2013;8:379–81.
[16] Quan Y, Xie H, Tian R, et al. Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. COPD 2014;11:171–6.
[17] Wang Y, Sun N, Cheng Z, et al. Optimal time to use low molecular weight heparin on prethrombotic state of rat chronic obstructive pulmonary disease model. Chin Med J (Engl) 2014;127:518–21.
[18] Zeng JH, Zeng J, Li YL, et al. Therapeutic effect of low molecular weight heparin on respiratory failure in acute exacerbation of chronic obstructive pulmonary disease. Chin Med Sci 2016;6:46–8.
[19] Zhao LY, Lu SF. Therapeutic effect of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease with respiratory failure. Guizhou Med 2016;40:482–3.
[20] Lin L, Zhang JH, Luo SP, et al. Therapeutic effect of low molecular weight heparin on patients with acute exacerbation of chronic obstructive pulmonary disease with respiratory failure. J Henan Univ Med Sci 2016;32:40–2.
[21] Zhao HD. Therapeutic effect of low molecular weight heparin on acute exacerbation of COPD with respiratory failure. J Clin Pulmonary Med 2009;14:809–10.
[22] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.
[23] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.